Early-stage lung cancer surgery is not the finish line. 🎯 What happens in the adjuvant setting determines whether your patient is alive eight years from now. The ADAURA Phase III trial just released its 8-year exploratory survival update, and the numbers are impossible to ignore. According to MyChesCo, adjuvant osimertinib reduced the risk of death by 47% compared with placebo in Stage II to IIIA EGFR-mutated NSCLC patients. That is the trial's primary population. Here is what that looks like in plain terms. Stage II-IIIA population (primary): 🔹 74% of Tagrisso-treated patients were alive at 8 years 🔹 58% of placebo patients were alive at 8 years 🔹 Hazard ratio: 0.53 (95% CI 0.38 to 0.75) Broader Stage IB-IIIA population: ...

A sign on the door. No warning. Five FQHC clinics just went dark. 🚨 The sign at the Berkeley Springs location read: "Our Office is facing an organizational emergency and our doors will be closed until further notice." That is not a press release. That is a handwritten notice taped to a door of a community health center that served 16,085 patients last year. This week, Tri-State Community Health Centers shut down five clinic locations across West Virginia, Maryland, and Pennsylvania with almost no notice. Patients showed up to appointments and found locked doors in Berkeley Springs, Hancock, Cumberland, and McConnellsburg. According to the Morgan Messenger, the closures were triggered by federal administrative requirements from HRSA, the U.S. Health Resources ...

More AI clearances won't save radiology. Smarter triage just might. 🩻 Everyone is debating whether AI will replace radiologists. But the real bottleneck in emergency radiology isn't intelligence. It's time. This week, a2z Radiology AI received FDA clearance for its Abdo-Triage software to flag 10 additional findings on abdomen-pelvis CT scans, according to Radiology Business. That brings the company's total triage portfolio to 17 findings across two FDA-cleared devices. A Boston-based startup founded in 2024. Already with two cleared products. That is not a slow regulatory story. That is a sprint. 🔹 The newly cleared product targets abdomen-pelvis CT, one of the most time-sensitive scan categories in emergency medicine. 🔹 The software is designed to help clinical teams triage a ...

$2.2 billion in ACA subsidies are coming back to taxpayers. 🔥 That number should stop everyone in healthcare in their tracks. On September 22, CMS announced it is canceling approximately 315,000 unauthorized enrollments in the Federal Health Insurance Marketplace, covering more than 760,000 individuals. According to the CMS press release, the agency expects this action to result in the return of roughly $2.2 billion in taxpayer-funded subsidies. Let that sink in for a second. 760,000 people. One enforcement action. $2.2 billion. This is not a small audit finding. This is a systemic failure in how the Marketplace was being administered, and it has been hiding in plain sight. 🔹 Since January 2026, CMS has issued termination notices for over 200 ...

70% of cancer deaths come from cancers with no recommended screening test. 🧬 That number stopped me cold when I read it in USA Today this week. We talk a lot about improving lung cancer screening rates. About getting more people into the pipeline for the five cancers that already have established screening. And that work is urgent and necessary. But 70% of cancer deaths are happening completely outside that pipeline. This week, the FDA's Molecular and Clinical Genetics Devices Panel voted in favor of GRAIL's Galleri multi-cancer early detection blood test. The vote on whether benefits outweigh risks: 7 to 2, with one abstention. The safety vote was unanimous. Here is what Galleri actually does: 🔹 It studies DNA ...

CFO, are you paying for a law that was supposed to protect your employees? 💥 Because that is exactly what is happening right now. This week, a coalition of 67 health care industry and advocacy groups sent a letter to congressional leadership calling the No Surprises Act arbitration process a "massive unforeseen crisis in employer-sponsored coverage." Those words belong to Melissa Bartlett, senior vice president for health policy at the ERISA Industry Committee. She is not a fringe voice. She speaks for the people managing the benefits your employees depend on. Here is what went wrong. The No Surprises Act, passed in 2020, did something genuinely good. It shielded patients from getting blindsided by out-of-network bills. That part worked. But ...

Europe just made a $100M bet that AI owns the clinic. 🏥 And the signal is bigger than the check. According to The Next Web, Tandem Health closed a $100m Series B led by the Scaleup Europe Fund, managed by EQT. Existing investors Kinnevik, Northzone, Amino Collective, and Visionaries joined the round. This brings the Stockholm-based company's total funding to $160m, following a $50m Series A in 2025. Here is what makes this round worth paying attention to. The Scaleup Europe Fund is an EU-backed vehicle. This is its first healthcare investment. Ever. When a sovereign-backed fund of that profile plants its first healthcare flag in a clinical AI company, that is not a portfolio decision. That is a policy ...

A radiation oncologist in a rural freestanding center opens the 2026 payment summary. CMS said the cut would be 1%. The actual number on the screen is 22%. That gap is not a rounding error. It is a structural failure with real consequences for cancer access. According to Newswise, citing an ASTRO statement submitted to CMS on September 14, 2026, more than two-thirds of radiation oncologists responding to an ASTRO survey reported payment declines of 10% or more following coding and payment changes implemented January 1. Many reported cuts of 20% to 30%. CMS had projected an overall reduction of just 1%. That is not a forecast miss. That is a policy credibility problem. I call this the Radiation Oncology ...

More patients. Less revenue. Same legal obligation to serve everyone. 🏥 Most people think Medicaid cuts mean fewer patients walk through the doors of community health centers. The opposite is true. According to Charta Health, FQHCs serve approximately 32 million patients annually, and Medicaid and CHIP accounts for roughly half of total patient volume. When coverage contracts, the patients do not disappear. They lose their insurance cards, then come back as uninsured or sliding-fee visits. The cost-to-serve stays exactly the same. The revenue does not. Section 330 of the Public Health Service Act is unambiguous: federally qualified health centers must serve every patient regardless of ability to pay. That mission mandate does not flex with policy shifts. That is the ...